Letter by Kan et al Regarding Article, “Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with interest the work by Massie et al,1 which reports that warfarin was associated with fewer nonfatal strokes than aspirin or clopidogrel and fewer admissions for worsening heart failure than aspirin in patients with reduced ejection fraction who are in sinus rhythm. Massie et al1 stated that a limitation relative to the higher number of diabetic patients in the warfarin group, with their higher risk, could have resulted in an underestimation of the ability of warfarin …